Pharmos
Corporation to Present at the BIO CEO & Investor Conference
Pharmos Also Selected by BIO to Represent "the Future
of Biotechnology" in Special Reception
Iselin
NJ, February 19, 2002 - Pharmos Corporation (Nasdaq:
PARS and Nasdaq Europe: PHRM) announced today it will
present to members of the financial community, the healthcare
industry and the media at the BIO CEO & Investor Conference
in New York on Friday, February 22, at 11:10 a.m. Eastern
Time. Organized by the Biotechnology Industry Organization
(BIO), the annual event is one of the largest biotechnology
and investor conferences on the East Coast. Pharmos' presentation
will outline the Company's progress toward solidifying
its position in the therapeutic marketplace for neurological
indications, including the status of its pivotal trial
of dexanabinol for traumatic brain injury and important
preclinical programs.
A
simultaneous webcast of Pharmos' presentation will be
available at http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=PARS&script=1020&item_id=w,601347,1,
and will be archived for a limited time after the conference.
Pharmos
will also participate in the International Reception &
Networking Exhibition at the Conference on Wednesday,
February 20, 2002. The theme of the Reception is "Passport
to the Future" and Pharmos is among 60 companies
BIO's Wall Street Advisory Board has selected that best
reflect this theme and represent the future of biotechnology.
Pharmos
Corporation discovers, develops and commercializes novel
therapeutics to treat a range of neurological disorders
associated with inflammatory processes, such as traumatic
brain injury, stroke, neuropathic pain, Parkinson's disease
and other CNS and peripheral neuro-inflammatory indications.
Statements
made in this press release related to future beneficial
expectations and projections of the Company are forward-looking
and are made pursuant to the safe harbor provisions of
the Securities Litigation Reform Act of 1995. Such statements
involve risks and uncertainties which may cause results
to differ materially from those set forth in these statements.
Additional economic, competitive, governmental, technological,
marketing and other factors identified in Pharmos' filings
with the Securities and Exchange Commission could affect
such results.
back
to News Room
